Skip to main content
Rare CancersGeneticsRare diseaseDiagnostics and screeningDiagnostic test

What this study is

This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.

What's being tested

  • FoundationOne CDx and FoundationOne Liquid CDx

    Intervention · DIAGNOSTIC TEST

    Eligible patients will have Foundation Medicine blood and tissue testing and have their results reviewed by the study's Virtual Molecular Tumor Board which, in turn, will make recommendations for treatment to treating physicians.

Study details

Sponsor
TargetCancer Foundation
Conditions
Rare Cancers · Cholangiocarcinoma · Cancer of Unknown Primary Site
Enrolling
400 people
Starts
2020-10-01
Est. completion
2028-12
Design
Open-label, non-randomized, factorial
Record
View on ClinicalTrials.gov ↗